{"classes":[{"categories":[{"measurements":[{"comment":"Upper and lower limits of 95% CI was not estimable due to smaller number of participants with the event.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"0.00"},{"groupId":"OG001","lowerLimit":"0.00","upperLimit":"0.07","value":"0.02"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"42"}],"units":"Participants"}],"title":"Year 1"},{"categories":[{"measurements":[{"comment":"Upper and lower limits of 95% CI was not estimable due to smaller number of participants with the event.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"0.00"},{"comment":"Upper and lower limits of 95% CI was not estimable due to smaller number of participants with the event.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"38"}],"units":"Participants"}],"title":"Year 2"}],"denoms":[{"counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"42"}],"units":"Participants"}],"description":"Surgery to bone events includes surgical procedures that are performed to set or stabilize pathologic fractures or areas of spinal cord compression and surgical procedures that are performed to prevent an imminent pathologic fracture or spinal cord compression.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 4 mg or a reduced dose, i.e., 3.5 mg, or 3.3 mg or 3.0 mg of Zoledronic acid as an IV infusion over a minimum of 15 minutes every 12 weeks for up to 96 weeks based on the participants most recent urine NTx measurement ( \\<50 nmol/mmol creatinine).","id":"OG000","title":"Zoledronic Acid Every 12 Weeks"},{"description":"Participants received 4 mg or a reduced dose, i.e., 3.5 mg, or 3.3 mg or 3.0 mg of Zoledronic acid as an IV infusion over a minimum of 15 minutes every 4 weeks or every 12 weeks for up to 96 weeks based on the participants most recent urine NTx measurement (≥ 50 nmol/mmol creatinine or \\<50 nmol/mmol creatinine, respectively).","id":"OG001","title":"Zoledronic Acid Every 4 Weeks or 12 Weeks"}],"paramType":"NUMBER","populationDescription":"ITT analysis set includes all participants who were enrolled in this study. Number analyzed signifies the number of participants with data available for analysis at given time point.","reportingStatus":"POSTED","timeFrame":"Years 1 and 2","title":"Percentage of Participants Who Experienced Surgery to Bone","type":"SECONDARY","unitOfMeasure":"percentage of participants"}